Molecular forms of cholinesterases in cerebrospinal fluid, blood plasma, and brain tissue of the beagle dog

A review of the reference dose for chlorpyrifos

Chlorpyrifos is an inhibitor of cholinesterase (ChE) and inhibition of ChE is believed to be the most sensitive effect in all animal species evaluated and in humans from previous evaluations. Recent literature, in particular epidemiology studies reporting associations between chlorpyrifos levels and fetal birth weight decreases, suggest the need to reevaluate the basis of the reference dose (RfD) for chlorpyrifos, however. In this paper, we evaluated newly available publications regarding chlorpyrifos toxicity and discuss the choice of critical effect--whether cholinesterase inhibition or developmental effect, the choice of appropriate species and study, the appropriate point of departure, and choice of uncertainty factors--including a discussion of the FQPA safety factor. We conclude that RBC cholinesterase inhibition is the critical effect, that human studies form the best choice of species--supported by a wealth of experimental animal data, that a NOAEL of 0.1 mg/kg/day is the most appropriate point of departure, and that a 10-fold factor for within human variability is sufficient to characterize the overall uncertainty in this rather large database. The resulting RfD is 0.01 mg/kg/day.

Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?

During the last decade, a systematic effort to develop a pharmacological treatment for Alzheimer disease (AD) has resulted in drugs being registered for the first time in the US and Europe for this specific indication. The 3 agents registered are cholinesterase inhibitors (ChEIs). The major therapeutic effect of ChEIs in patients with AD is the maintenance of cognitive function, as compared with placebo, during a 6-month to 1-year period of treatment. Additional drug effects that may occur are the slowing of cognitive deterioration and improvement of behaviour and daily living activities. Comparison of clinical effects of 6 ChEIs demonstrates a rather similar magnitude of improvement in cognitive outcome measures. For some drugs, this level may represent an upper limit, while for others it may be possible to increase the benefit further. In order to maximise and prolong positive drug effects it is important to start treatment early and adjust the dosage during treatment. Recent studies that used this administration strategy have shown that in many patients, the stabilisation effect produced by ChEIs can be prolonged for as long as 36 months. This long-lasting effect suggests mechanisms of action other than symptomatic ones. In this article, the effects of ChEIs on beta-amyloid metabolism are postulated to explain the stabilising (i.e. disease-modifying) effects of the drugs. Evidence for such a mechanism is available at the experimental but not yet at the clinical level.

Diffuse transmission by acetylcholine in the CNS

Recent immunoelectron microscopic studies have revealed a low frequency of synaptic membrane differentiations on ACh (ChAT-immunostained) axon terminals (boutons or varicosities) in adult rat cerebral cortex, hippocampus and neostriatum, suggesting that, besides synaptic transmission, diffuse transmission by ACh prevails in many regions of the CNS. Cytological analysis of the immediate micro-environment of these ACh terminals, as well as currently available immunocytochemical data on the cellular and subcellular distribution of ACh receptors, is congruent with this view. At least in brain regions densely innervated by ACh neurons, a further aspect of the diffuse transmission paradigm is envisaged: the existence of an ambient level of ACh in the extracellular space, to which all tissue elements would be permanently exposed. Recent experimental data on the various molecular forms of AChE and their presumptive role at the neuromuscular junction support this hypothesis. As in the peripheral nervous system, degradation of ACh by the prevalent G4 form of AChE in the CNS would primarily serve to keep the extrasynaptic, ambient level of ACh within physiological limits, rather than totally eliminate ACh from synaptic clefts. Long-lasting and widespread electrophysiological effects imputable to ACh in the CNS might be explained in this manner. The notions of diffuse transmission and of an ambient level of ACh in the CNS could also be of clinical relevance, in accounting for the production and nature of certain cholinergic deficits and the efficacy of substitution therapies.

Brain and cerebrospinal fluid cholinesterases in Alzheimer's disease, Parkinson's disease and aging. A critical review of clinical and experimental studies

Acetylcholinesterase (AChE), an enzyme responsible for the break-down of acetylcholine, is found both in cholinergic and non-cholinergic neurons in the central nervous system. In addition to its role in the catabolism of acetylcholine, AChE have other functions in brain, e.g. in the processing of peptides and proteins, and in the modulation of dopaminergic neurons in the brain stem. Several clinical and experimental studies have investigated AChE in brain and cerebrospinal fluid (CSF) in aging and dementia. The results suggest that brain AChE and its molecular forms show interesting changes in dementia and aging. However, CSF-AChE activity is not a very reliable or sensitive marker of the integrity and function of cholinergic neurons in the basal forebrain complex. Additional work is needed to clarify the role of AChE abnormality in the formation of pathology changes in patients with Alzheimer's disease.

Plasma and serum G4 isoenzyme of acetylcholinesterase in patients with Alzheimer-type dementia and vascular dementia

We developed a new assay for plasma or serum G4 acetylcholinesterase (AChE) activity. There was no difference in G4 AChE activity between serum and plasma. Plasma AChE activity in control subjects (8-92 years) was independent of age. Serum G4 AChE activity was significantly increased in patients with vascular dementia (P less than 0.01), compared with age-matched control, and significantly decreased in those with probable Alzheimer-type dementia (P less than 0.02). The difference between VD and ATD was significant (P less than 0.001), and thus the measurement of plasma or serum G4 AChE activity would be helpful in the differential diagnosis of dementia.

Cerebrospinal fluid changes in experimental cardiac arrest (maximal stress)

Cardiac arrest produces a prompt and maximal increase of plasma catecholamines, with associated elevations of the hormones involved in the endocrine response to stress. To investigate the participation of the central nervous system (CNS) in the generation of the endocrine response, the catecholamines epinephrine and norepinephrine in cerebrospinal fluid (CSF) were measured before, during, and after cardiac arrest accompanied by cardiopulmonary resuscitation (CPR) in adrenalectomized (ADX) and sham-operated (SHAM) dogs. We also determined the activity of acetylcholine esterase (AChE), an intracellular enzyme released into the CSF after hypothalamic or caudate stimulation. During CPR, plasma epinephrine increased significantly in SHAM but not ADX dogs, increasing from (mean +/- SE) 480 +/- 171 to 29,800 +/- 14,200 pg/ml (P less than 0.05). Prearrest CSF norepinephrine was higher in ADX than SHAM dogs and increased in both groups with cardiac arrest, but the increase was significant only in SHAM animals; CSF epinephrine remained unchanged during or after cardiac arrest. CSF AChE activity increased during and after defibrillation; the difference with basal levels became significant when the peak postarrest values were considered (P less than 0.05). These results document biochemical changes occurring in the CNS during maximal stress represented by cardiac arrest. It is suggested that CSF norepinephrine and AChE activity elevations are markers for hypothalamic activation from the stress of cardiac arrest.

Release of acetylcholinesterase from the caudate nucleus of the rat

Acetylcholinesterase (AChE) can be released in the perfusate of rat caudate nucleus (CN) slices by two different modes of stimulation, with electrical stimulation at 5 Hz and with high concentrations of K+ (105 mM) using K+-propionate. We were unable to demonstrate AChE release with lower K+ concentrations (50 mM); however, at this concentration the drop in AChE activity seen in resting conditions was prevented. Practically all (95%) cholinesterase (ChE) found in the rat CN is AChE, which is represented by two major molecular forms (4S and 10S). In the perfusate, only AChE activity could be detected. A comparison of acetylcholine (ACh) and AChE release showed that maximal 3H-outflow and AChE release occurred at the same frequency (5 Hz), but the onset of AChE release was delayed. With high K+ (105 mM) depolarization, AChE release started after termination of the stimulation and continued for at least 50 min. These findings are consistent with the view that soluble form(s) of AChE can be slowly released from neurons under specific conditions of depolarization. In the caudate of the rat, the most likely sites for this release are processes of cholinergic interneurons. A hypothesis of AChE release is presented, and possible physiological and pathological implications of such a mechanism are discussed.

Molecular forms of cholinesterases in CSF of Alzheimer's disease/senile dementia of Alzheimer type patients and matched neurological controls

Acetylcholinesterase, pseudocholinesterase and their molecular forms were measured in the CSF of patients affected by Alzheimer's disease and of matched neurological controls. Three different molecular forms of ChE were found in the CSF of both groups of patients, but only two of them belonged to 'true' AChE. No differences were found between Alzheimer's disease patients and neurological controls in all the examined parameters.

Cholinesterases in cerebrospinal fluid. Correlations with clinical measures in Alzheimer's disease

Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid were measured in 17 patients with Alzheimer's disease and 6 control patients, as potential clinical measures of impaired cholinergic neurotransmission in Alzheimer's disease. The activity of butyrylcholinesterase was decreased in patients with Alzheimer's disease compared to that observed in control patients, but there was overlap between values in the 2 groups. Low butyrylcholinesterase activity was correlated with severity of dementia, memory impairment, and language disorder. Acetylcholinesterase activity was significantly correlated with visual contrast sensitivity, but not with dementia severity, and did not differentiate patients with Alzheimer's disease from control cases. These results suggest that cholinesterases in cerebrospinal fluid are related to brain cholinesterases, and indicate that the activities of acetylcholinesterase and butyrylcholinesterase should be distinguished in studies of cerebrospinal fluid.

Properties of acetylcholinesterase and non-specific cholinesterase in rat superior cervical ganglion and plasma

Amphiphile dependency, solubility in aqueous solutions, and sensitivity to proteolysis of acetylcholinesterase (AChE) and nonspecific cholinesterase (nsChE) in the rat superior cervical ganglion were studied and compared to properties of soluble plasma cholinesterases. Ganglion AChE shows strong amphiphile dependency: an amphyphilic substance must be present in the homogenizing medium in order to obtain maximal apparent enzyme activity. Apparent activity of AChE solubilized in Ringer's solution was also increased after subsequent addition of a detergent. The 4 S molecular form, predominant in this extract (corresponding to the fastest electrophoretic band), is very sensitive to papain proteolysis but can be protected by a detergent. This molecular form therefore carries an important hydrophobic domain and is probably membrane bound in situ. The 10 S form of ganglionic AChE, extracted in Ringer's solution, is probably a soluble enzyme since, like soluble plasma enzymes, it is not amphiphile dependent and is rather resistant to proteolysis. Ganglion nsChE is more water soluble, less amphiphile dependent and more protease resistant than AChE.

Changes in the levels and forms of rat plasma cholinesterases during chronic diisopropylphosphorofluoridate intoxication

The effect of chronic administration of diisopropylphosphorofluoridate (DFP) on the levels and forms of plasma cholinesterase (ChE), were studied in male Wistar albino rats sacrificed at different time intervals after various schedules of treatment. In particular the inhibition and recovery rate of the enzymatic activity was evaluated for butyrylcholinesterase (BuChE), determined using butyrylthiocholine (BuThCh) as substrate and for acetylcholinesterase (AChE), measured using acetylthiocholine (AcThCh) in the presence of iso-OMPA 0.1 mM. At 1 1/2 and 24 hr after the DFP treatments, BuChE was considerably more depressed than was the case for AChE. Moreover, the recovery of BuChE proceeded more slowly, its activity being restored only seven days after the last treatment, while the recovery of AChE was completed 72 hr after the end of the treatments. Plasma molecular forms were separated by polyacrylamide gel electrophoresis and were revealed by enzymatic reaction with BuThCh or AcThCh as substrates. By using selective inhibitors, five main molecular forms of BuChE and two of AChE were found to exist in control plasma samples. A differential inhibition and recovery rate was observed among these forms after DFP intoxication. At 1 1/2 hr after the treatments, the BuChE activity was too low to be detected on the gels, but 24 hr thereafter, the quantitative determination of the different forms, performed by scanning densitometry, showed a significant increase of the two faster migrating ones. At the following time intervals, the electrophoretic pattern returned progressively towards normality. The faster migrating forms are therefore probably the first synthesized in the process of recovery of BuChE activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Acetylcholinesterase molecular forms from rat and human erythrocyte membrane

1. Some of the biochemical characteristics of acetylcholinesterase from rat and human erythrocytes were studied. 2. Both for rat and man two different acetylcholinesterase molecular forms were identified by gel electrophoresis. The faster moving form is less conspicuous and is not present in all individuals, therefore single-banded and double-banded preparations of red cell acetylcholinesterase can be obtained. The two components appear to be isomers of different molecular size (approximately Mr 150 000 and Mr 245 000) as estimated by gel electrophoresis at different polyacrylamide concentrations. 3. A single band, with a molecular weight of approximately 135 000, was obtained by sodium dodecyl sulphate gel electrophoresis. These results suggest that the faster moving form is a protomer and the slower a dimer. 4. The different sedimentation values obtained by density gradient centrifugation in the presence of Triton X-100 of double-banded (5.3S) and single-banded (6.3S) rat and human acetylcholinesterase preparations, are consistent with a protomer-dimer hypothesis. 5. The isoelectric pattern observed for both double- and single-banded preparations was similar for rat and man acetylcholinesterase and showed a considerable microheterogeneity (thirteen activity bands for rat and eleven for man with isoelectric values from 4.6 to 5.9).